Topic 255 development of a targeted therapy for acute myeloid

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201100093C
Awardee
Awarding agency
Obligated
$199,833

Award facts

Contract value 100% obligated
$199,833.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 45 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Cleveland, OH 44106, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $199,833

About this award

This is a $199,833 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Cleveland Leukemia Therapeutics LLC, a small business contractor, for the development of a targeted therapy for acute myeloid leukemia. The contract has a completion date of September 29, 2012 and was awarded on September 30, 2011. This award appears to be part of the agency's TAS 75 0849 program focused on Topic 255 for the development of targeted therapies.

Quick answers

Who was awarded contract HHSN261201100093C?

HHSN261201100093C was awarded to Cleveland Leukemia Therapeutics LLC by National Cancer Institute (National Institutes of Health) on September 30, 2011.

How much is contract HHSN261201100093C worth?

The government has obligated $199,833 on HHSN261201100093C.

Was contract HHSN261201100093C competed?

The extent of competition for HHSN261201100093C was full and open competition after exclusion of sources. The government received 45 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award